Last quarter (Q ), US Stem Cell's total revenue was $8.05K, a decrease of -65.88% from the same quarter last year. In Q, US Stem Cell's net income was $3.03M. See US Stem Cell’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 66.54K	$ 66.54K	$ 200.75K	$ 277.09K	$ 3.07M	$ 6.70M
Cost of Revenue	$ -23.77K	$ -23.77K	$ -52.03K	$ 64.12K	$ 1.34M	$ 2.11M
Gross Profit	$ 58.28K	$ 58.28K	$ 252.78K	$ 212.97K	$ 1.74M	$ 4.59M
Operating Expense	$ -1.78M	$ -1.78M	$ -2.28M	$ 2.61M	$ 5.15M	$ 5.69M
Operating Income	$ 1.88M	$ 1.88M	$ 2.54M	$ -2.40M	$ -3.42M	$ -1.10M
Net Non Operating Interest Income Expense	$ -689.98K	$ -689.98K	$ -1.00M	$ -488.37K	$ -981.00K	$ -1.44M
Other Income Expense	$ -442.37K	$ 447.48K	$ 151.41K	$ -1.88K	$ 562.52K	$ 382.28K
Pretax Income	$ -2.86M	$ -2.86M	$ 1.39M	$ -2.89M	$ -3.84M	$ -2.16M
Tax Provision	$ -1.52M	$ -1.52M	$ -1.02M	$ 0.00	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ 743.48K	$ 747.12K	$ 1.39M	$ -2.89M	$ -3.84M	$ -2.16M
Basic EPS	$ >-0.01	-	-	$ -0.01	$ -0.01	$ -0.01
Diluted EPS	$ >-0.01	-	-	$ -0.01	$ -0.01	$ -0.01
Basic Average Shares	$ 1.12B	-	-	$ 429.29M	$ 398.04M	$ 365.64M
Diluted Average Shares	$ 1.12B	-	-	$ 429.29M	$ 398.04M	$ 365.64M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ -2.62M	$ -1.80M	$ -2.34M	$ 2.68M	$ 6.49M	$ 7.80M
Net Income From Continuing And Discontinued Operation	$ -2.86M	$ -2.86M	$ 1.39M	$ -2.89M	$ -3.84M	$ -2.16M
Normalized Income	$ -1.28M	-	-	$ -2.91M	$ -3.96M	$ -2.29M
Interest Expense	$ 329.49K	-	-	$ 488.37K	$ 981.00K	$ 1.44M
EBIT	$ -2.17M	$ -2.17M	$ 2.39M	$ -2.40M	$ -2.85M	$ -715.62K
EBITDA	$ -1.81M	$ -1.48M	$ 3.36M	$ -2.40M	$ -2.61M	$ -508.49K

Currency in USD

US Stem Cell Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing